Europe Platelet Rich Plasma Market

Europe Platelet-Rich Plasma Market Size (2024 to 2029)

The platelet-rich plasma market size in Europe is estimated to be USD 179.51 Million by 2029 and USD 95.01 Million by 2024, growing at a CAGR of 13.57% from 2024 to 2029.

The adoption of PRP treatment is growing considerably in the European region owing to the rising beauty consciousness among the European population. PRP is a minimally invasive surgery and does not require any incisions or stitches. The PRP therapy can be used for various health purposes, such as hair loss, acne scarring, wrinkles, and age spots. In PRP therapies, platelets encourage the production of new skin cells and collagen that aids the skin's health and promotes beauty. Factors such as the growing incidence of sports injuries and increasing awareness among people regarding the benefits of PRP therapies among healthcare providers and patients are majorly accelerating the European PRP market growth. For instance, an estimated 6.2 million people above 15 years in Europe are admitted to hospitals annually due to sports injuries. In Austria, 29 in 1000 people have injuries from sports every year.

In addition, the growing patient population suffering from musculoskeletal diseases is another major factor fuelling the PRP market growth in the European region. Furthermore, the growing aging population and increasing R&D activities around improving the effectiveness of the PRP are contributing to the growth of the European PRP market. Furthermore, the presence of a skilled workforce who can handle the latest PRP equipment and perform PRP therapies in the European region is promoting the growth of the Europe PRP market. Microneedling with PRP, hair restoration with PRP, and facial rejuvenation with PRP are some of the famous PRP therapies in the European region. In addition, the rising demand from people for non-surgical cosmetic treatments is another notable factor promoting the European PRP market growth.

However, the lack of consistency in the preparation and quality of blood concentrate and platelet separation operations is hampering the market growth in this region. Unfavorable reimbursement rules for devices and quality control and test results issues further inhibit the market growth. High prices involved with treatment procedures and uncertainties associated with the platelet-rich plasma's therapeutic efficacy further limit the PRP market's growth rate in the European region.

This research report on the European platelet-rich plasma market has been segmented and sub-segmented into the following categories.

Europe Platelet-Rich Plasma Market Analysis By Application

• Orthopedics
• Cosmetic Surgery
• Ophthalmic Surgery
• Neurosurgery

Europe Platelet-Rich Plasma Market Analysis By Product

• Pure
• Leukocyte-Rich
• Leukocyte-Rich Fibrin

Europe Platelet-Rich Plasma Market Analysis By Origin

• Homologous PRP
• Autologous PRP
• Allogeneic PRP    

Europe Platelet-Rich Plasma Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the Eastern European market shows promising growth potential and is estimated to be playing a crucial role in the European market during the forecast period, which currently occupies the second-largest share in the global market.

The German PRP market accounted for the largest share of the European region in 2021. The growing awareness of platelet-rich plasma therapies in Germany is one of the factors potentially supporting the market growth in this country. In Germany, PRP has been used for orthopedics, dermatology, and dentistry. Therefore, the growing demand for regenerative medical treatments in Germany is one of the major factors contributing to the German market growth. In addition, the growing aging population, increasing awareness among people regarding PRP benefits, and rapid adoption of advanced technologies in Germany are propelling the German PRP market growth.

The UK PRP market is another promising region in the European region and is projected to grow at a CAGR of 8% during the forecast period. The adoption of PRP therapies is growing rapidly in the UK. Factors such as the growing prevalence of sports injuries and increasing awareness regarding the benefits associated with PRP therapies support the UK Platelet Rich Plasma Market.

The French PRP market is the second largest PRP market in the European region and is predicted to maintain its position throughout the forecast period witnessing a CAGR of 6.5%. Therefore, France is a potential market for PRP in the European region. The awareness and adoption of PRP in France are growing rapidly.

KEY MARKET PLAYERS

A few notable companies in the European platelet-rich plasma market profiled in this report are DR. PRP AMERICA, LLC, Glofinn Oy, Zimmer Biomet, DePuy Synthes, Emcyte Corporation, Terumo BCT, Anthrex Inc, T-Biotechnology and Stryker.